Homologous Recombination Deficiency Test (HRD) – RAPID

Test Code
SLS162203
Book Now

What is the Homologous Recombination Deficiency Test – RAPID?

This is an accelerated version of the standard HRD test designed to deliver faster results. It evaluates BRCA1, BRCA2, and genomic instability in tumor tissue, making it ideal for patients requiring urgent treatment decisions.

Genes Covered/ No. of Genes/ Biomarkers Covered: 19 genes (including BRCA1 and BRCA2) and Genomic Scar Score (GSS)

Who Is This Test For?

Patients with rapidly progressing ovarian cancer, where immediate therapeutic decisions are critical

Key Features

  • Rapid analysis of BRCA1 and BRCA2 mutations and Genomic Scar Score to assess homologous recombination deficiency
  • Detects PARPi-sensitive tumors, especially without BRCA mutations
  • Demonstrates high concordance with HRD diagnostics used in clinical trials

Clinical Applications

  • Accelerates treatment planning with quicker diagnostic insights
  • Identifies eligibility for PARP inhibitors
  • Supports personalized treatment strategies under time-sensitive conditions

Ovarian Cancers

Contact Us